Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
173 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
22 Recruiting A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
23 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
24 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
25 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
26 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
27 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
28 Not yet recruiting Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia - Chronic Phase
Interventions: Drug: Dasatinib 100 MG [Sprycel];   Drug: Nilotinib 150mg oral capsule [Tasigna]
29 Not yet recruiting Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention:
30 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
31 Recruiting Allogeneic SCT for CML, TKI Failure After TKI Failure
Condition: Chronic Myeloid Leukemia
Intervention:
32 Recruiting Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia;   Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Drug: Nilotinib
33 Recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
34 Not yet recruiting Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: ABL001;   Drug: Bosutinib
35 Recruiting Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Condition: Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
36 Recruiting Preparatory Work to Assess Adherence to Oral Chemotherapy
Condition: Chronic Myeloid Leukemia
Intervention:
37 Not yet recruiting Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
38 Recruiting Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib (Tasigna ®), capsules of 150 mg;   Drug: Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)
39 Not yet recruiting 2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML
Condition: Chronic Myeloid Leukemia
Interventions: Other: TKI discontinuation;   Drug: nilotinib
40 Recruiting Radotinib as 3rd or Later Line Therapy in CP-CML
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Radotinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.